Search Results

SciBase Holding AB, a leading developer of augmented intelligence-based solutions for skin disorders announced that they have entered into a collaboration agreement with the Skin and Cancer Institute to pilot Nevisense in several of their California locations.

SciBase Holding AB, a leading developer of augmented intelligence-based solutions for skin disorders hereby announces that Dan Walker has been appointed as VP US Commercial Operations.

Vitrolife AB has completed the acquisition of eFertility as previously communicated in the press release on 2 May 2024.

SciBase Holding AB, a leading developer of augmented intelligence-based solutions for skin disorders announced that they have entered into a collaboration agreement with Schweiger Dermatology group to pilot Nevisense in their Freehold, NJ office.

Medivir AB announces that the number of shares and votes in Medivir has changed during June 2024 as a result of the issue of 1,700,000 shares of series C and the reclassification of 114 587 shares of series C to ordinary shares which was carried out as a part of the implementation of the incentive program resolved by the general meeting on 7 May 2024.

Vitrolife AB signed an agreement to acquire 100% of the shares in eFertility. This acquisition is a key element of the Vitrolife Group’s strategy to bring increased standardisation and digitalisation to IVF clinics around the world.

AB Science SA (Euronext - FR0010557264 - AB) today announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a trending toward a negative opinion on the application for conditional marketing authorisation of masitinib in the treatment of amyotrophic lateral sclerosis (ALS), following an oral explanation held at the 28 May meeting of the CHMP.